Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2006 1
2007 2
2008 3
2009 5
2010 7
2011 9
2012 13
2013 9
2014 10
2015 14
2016 10
2017 9
2018 8
2019 15
2020 10
2021 14
2022 5
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 31889144

133 results

Results by year

Filters applied: . Clear all
Page 1
Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study.
O'Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, Lechowicz MJ, Savage KJ, Shustov AR, Gisselbrecht C, Jacobsen E, Zinzani PL, Furman R, Goy A, Haioun C, Crump M, Zain JM, Hsi E, Boyd A, Horwitz S. O'Connor OA, et al. J Clin Oncol. 2011 Mar 20;29(9):1182-9. doi: 10.1200/JCO.2010.29.9024. Epub 2011 Jan 18. J Clin Oncol. 2011. PMID: 21245435 Free PMC article. Clinical Trial.
Pralatrexate experience in PTCL: A multicenter retrospective study from Turkey.
Sinan Dal M, Merdin A, Erkurt MA, Ekinci Ö, Albayrak M, Kabukcu Hacıoglu S, Kaya A, Dogu MH, Hindilerden F, Sarici A, Merter M, Reis Aras M, Akgun Caglıyan G, Kizil Cakar M, Aydogdu I, Kuku I, Korkmaz S, Ulas T, Eser B, Altuntas F. Sinan Dal M, et al. J BUON. 2021 Jul-Aug;26(4):1536-1539. J BUON. 2021. PMID: 34565016 Free article.
Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study.
Foss F, Horwitz SM, Coiffier B, Bartlett N, Popplewell L, Pro B, Pinter-Brown LC, Shustov A, Furman RR, Haioun C, Koutsoukos T, O'Connor OA. Foss F, et al. Clin Lymphoma Myeloma Leuk. 2012 Aug;12(4):238-43. doi: 10.1016/j.clml.2012.01.010. Epub 2012 Apr 26. Clin Lymphoma Myeloma Leuk. 2012. PMID: 22542448 Clinical Trial.
A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma.
Amengual JE, Lichtenstein R, Lue J, Sawas A, Deng C, Lichtenstein E, Khan K, Atkins L, Rada A, Kim HA, Chiuzan C, Kalac M, Marchi E, Falchi L, Francescone MA, Schwartz L, Cremers S, O'Connor OA. Amengual JE, et al. Blood. 2018 Jan 25;131(4):397-407. doi: 10.1182/blood-2017-09-806737. Epub 2017 Nov 15. Blood. 2018. PMID: 29141948 Free PMC article. Clinical Trial.
Pralatrexate induced durable response in a relapsed/refractory peripheral T-cell lymphoma patient with a history of autologous stem cell transplantation: Case report of a patient followed-up over 3 years under pralatrexate treatment.
Merdin A, İskender D, Ulu BU, Doğan M, Çakar MK, Dal MS, Altuntaş F. Merdin A, et al. Medicine (Baltimore). 2019 Jul;98(30):e16482. doi: 10.1097/MD.0000000000016482. Medicine (Baltimore). 2019. PMID: 31348254 Free PMC article.
133 results